Identification of the likely translational start of Mycobacterium tuberculosis GyrB
© Karkare et al.; licensee BioMed Central Ltd. 2013
Received: 14 February 2013
Accepted: 8 July 2013
Published: 15 July 2013
Bacterial DNA gyrase is a validated target for antibacterial chemotherapy. It consists of two subunits, GyrA and GyrB, which form an A2B2 complex in the active enzyme. Sequence alignment of Mycobacterium tuberculosis GyrB with other bacterial GyrBs predicts the presence of 40 potential additional amino acids at the GyrB N-terminus. There are discrepancies between the M. tuberculosis GyrB sequences retrieved from different databases, including sequences annotated with or without the additional 40 amino acids. This has resulted in differences in the GyrB sequence numbering that has led to the reporting of previously known fluoroquinolone-resistance mutations as novel mutations.
We have expressed M. tuberculosis GyrB with and without the extra 40 amino acids in Escherichia coli and shown that both can be produced as soluble, active proteins. Supercoiling and other assays of the two proteins show no differences, suggesting that the additional 40 amino acids have no effect on the enzyme in vitro. RT-PCR analysis of M. tuberculosis mRNA shows that transcripts that could yield both the longer and shorter protein are present. However, promoter analysis showed that only the promoter elements leading to the shorter GyrB (lacking the additional 40 amino acids) had significant activity.
We conclude that the most probable translational start codon for M. tuberculosis GyrB is GTG (Val) which results in translation of a protein of 674 amino acids (74 kDa).
Bacterial DNA gyrase is a validated target for antibacterial chemotherapy . It is a member of the DNA topoisomerase family of enzymes, which are responsible for maintaining and manipulating the topological state of DNA [2, 3]. These enzymes are required for vital processes such as DNA replication, transcription, recombination and chromatin remodelling. Topoisomerases can be classified into two types, I and II, dependent on whether their reactions involve transient cleavage of one (I) or both (II) strands of DNA. Due to the important role played by topoisomerases in maintaining cell viability, they are attractive clinical targets for chemotherapeutics [1, 4, 5].
DNA gyrase is a type II topoisomerase that consists of two subunits, GyrA and GyrB, which form an A2B2 complex in the active enzyme [1, 6]. Gyrase introduces negative supercoils into DNA, in addition to catalysing relaxation and decatenation. The supercoiling and decatenation reactions require ATP hydrolysis, which occurs in the GyrB subunits. The absence of gyrase in most eukaryotes and its essentiality in bacteria have made it an ideal target for antimicrobial agents .
Tuberculosis (TB) is the world’s most deadly bacterial disease with around a third of the world’s population infected and over 1 million deaths every year . Although treatments are available, drug-resistant strains, MDR (multi-drug resistant) and XDR (extensively drug resistant) TB, pose serious problems. Moxifloxacin, a fluoroquinolone that targets DNA gyrase, has been successfully used against Mycobacterium tuberculosis, particularly MDR strains . The search for new anti-TB agents involves the further exploitation of M. tuberculosis gyrase as a target for TB therapy and a need to achieve a greater understanding of this enzyme.
Most of our current information about gyrase concerns the enzyme from Escherichia coli, a Gram-negative bacterium, with limited information about gyrase from M. tuberculosis, which is generally described as a Gram-positive bacterium. In M. tuberculosis the two genes encoding DNA gyrase, gyrB and gyrA, are located adjacent to each other, and although there is a separate promoter for gyrA (PA), the primary transcript appears to be dicistronic . Analysis of the region upstream of gyrB suggests there are multiple promoters, but it appears that most of the transcripts originate from PB1 with the others potentially involved in the fine-tuning of transcription .
There are significant discrepancies in the M. tuberculosis GyrB sequences retrieved from different databases. For example, in the case of NCBI code CAB02426 for M. tuberculosis H37Rv GyrB, 40 additional amino acids are present in the sequence starting with amino acids MGKNEARRSA. While the same protein cross-referenced in UniProtKB/Swiss-Prot as P0C5C5 lacks these additional amino acids; it is 674 amino acids and starts with the amino acid sequence: MAAQKKKAQD. This is not uniform across UniProtKB/Swiss-Prot as in other M. tuberculosis strains, such as M. tuberculosis T92, the GyrB sequence (UniProtKB/Swiss-Prot: D5XPA3) also has the 40 additional amino acids and starts with MGKNEARRSA. Similarly, in the case of M. bovis AF2122/97 both the NCBI (CAD92867) and UniProtKB/Swiss-Prot (Q7U312) databases indicate the presence of an additional 40 amino acids at the GyrB N-terminus. Re-annotation of the M. tuberculosis H37Rv gene sequence  suggested that GyrB is a protein of 714 amino acids and MW 78.4 kDa, These various discrepancies in GyrB sequence annotation have led to differences in sequence numbering, which in turn has resulted in the reporting of previously known fluoroquinolone resistance mutations as novel mutations .
In this paper we investigate the start codon for M. tuberculosis GyrB sequence by promoter and transcript analysis, and studies on the expressed protein.
Materials and methods
Preparation and purification of proteins
M. tuberculosis gyrB sequences were amplified from M. tuberculosis genomic DNA and cloned into TOPO® cloning vectors followed by sub-cloning into pET20 using the ClonableTM Ligation kit (Novagen). Expression and purification of the GyrB and GyrA proteins were as previously described .
M. tuberculosis DNA gyrase assays (supercoiling, relaxation and decatenation) were performed as described previously . Peptide mass fingerprinting and mass spectrometry analyses were carried out by Gerhard Saalbach (John Innes Centre Proteomics Shared Facility).
Primer pairs Met-F: 5′-AGT ACT CAC GTC GAT CGG CCC AGA ACA AGG CGC- 3′ and Met-R: 5′-CCC GGG CAT CTA ACC GCG CCG TGC-3′ or Val-F: 5′-AGT ACT CAC GTC GAT CGG CCC AGA ACA AGG CGC-3′ and Val-R: 5′-CCC GGG CAC GAT CCG AAT ACT CTC CTC AGG G-3′ were used to amplify the upstream regions. The thermocycler program used was: 2 min denaturation at 94°C, 25 cycles of 94°C for 15’, 55°C for 1’, and 72°C for 2’, with a final extension at 72°C for 10’. PCR products were cloned into the pGEM-T easy vector (Promega), sequence verified, and sub-cloned as Sca I fragments into pSM128  to construct the plasmids, which were called: pSM128-Met, carrying 128 bp upstream of the predicted transcriptional start site (nucleotides 4998–5125, ending with Met); and pSM128-Val (4998–5242) carrying a larger 245 bp upstream region ending with Val (GTG). Plasmids were introduced into M. tuberculosis H37Rv by electroporation and selected on streptomycin. Three individual transformants were inoculated into 10 ml of standing cultures (7H9-Tw medium Middlebrook 7H9 liquid medium supplemented with 10% (vol/vol) OADC (oleic acid, bovine serum albumin, d-glucose, catalase; Becton Dickinson) and 0.05% (wt/vol) Tween 80). Cell-free extracts were prepared and β-galactosidase assays were performed, as previously described .
Sequence alignment of M. tuberculosis GyrB
Enzyme activity of GyrBs with and without the additional 40 amino acids
Expression plasmids (based on pET20) were constructed for production of GyrBs with and without the additional 40 amino acids, and the resulting proteins were purified by affinity chromatography and by gel filtration. The presence of the additional 40 amino acids in the longer GyrB was verified by peptide mass fingerprinting and mass spectrometry analysis (data not shown).
The two GyrB proteins were complexed with M. tuberculosis GyrA and the supercoiling, relaxation and decatenation activities were measured as previously described . We found that there was no significant effect of the additional amino acids on these activities, for example the supercoiling activities of the two enzymes are nearly identical (Additional file 1: Figure S1), and no effect on the sensitivity of the enzyme to novobiocin (data not shown); the binding site for novobiocin lies in the N-terminal domain of GyrB . This strongly suggests, in vitro at least, that the additional 40 amino acids are of no functional significance.
Identification of the M. tuberculosis gyrB transcript
We wanted to determine whether GyrB was produced as the longer or shorter protein; as a first step we analysed the transcripts. RT-PCR was performed to determine which GyrB mRNA transcripts are produced in M. tuberculosis under normal aerobic growth. Primers were designed to distinguish between longer and shorter transcripts which could encode for longer or shorter proteins respectively (Figure 1A). As shown in Figure 1B, PCR products were obtained with all primer sets (F1, F2, F3, F4) indicating that mRNA was being produced that could potentially encode the longer protein. The identity of the products obtained was confirmed by sequencing. This RT-PCR experiment indicates that the nucleotide sequence that could encode the 40 amino acids is transcribed.
Sequence alignments of GyrBs from different bacterial species suggest that 40 additional amino acids could potentially be present at the M. tuberculosis GyrB N-terminus (Figure 2). In order to study the effect of these 40 amino acids on enzyme activity, we expressed and purified GyrB proteins in which the 40 amino acids were present or absent and found that there is no apparent effect of the additional amino acids on gyrase activity, as judged by supercoiling, relaxation and decatenation assays in vitro.
RT-PCR experiments were performed, which showed that the RNA sequence corresponding to the additional 40 amino acids at the GyrB N-terminus is present at the transcript level (Figure 1). However, promoter assays (Figure 3B) showed that only the shorter GyrB would be expressed at a significant level in vivo. These experiments suggest that the promoter elements are present in the region corresponding to the predicted 40 amino acids at the GyrB N-terminus (Figure 3C). The presence of transcripts containing the 40 amino acid region indicates possible post-transcriptional events occurring before the mature GyrB is formed.
Taken together our results support M. tuberculosis GyrB being a protein of 74,058.7 Da (674 amino acids) that begins with the codon GTG (Val) at position 5240–5242 in the M. tuberculosis genome sequence . A recent paper also supports this conclusion .
This work was supported by an EST early stage research scholarship, EU FP7 (to SK) and by grant BB/J004561/1 from BBSRC and the John Innes Foundation to AM, and by European Union Project LSHP-CT-2005-018923. We thank Fred Collin for comments on the manuscript.
- Collin F, Karkare S, Maxwell A: Exploiting bacterial DNA gyrase as a drug target: current state and perspectives. Appl Microbiol Biotechnol. 2011, 92 (3): 479-497. 10.1007/s00253-011-3557-z.PubMedPubMed CentralView ArticleGoogle Scholar
- Bates AD, Maxwell A: DNA Topology. 2005, Oxford: Oxford University PressGoogle Scholar
- Schoeffler AJ, Berger JM: DNA topoisomerases: harnessing and constraining energy to govern chromosome topology. Q Rev Biophys. 2008, 41 (1): 41-101.PubMedView ArticleGoogle Scholar
- Pommier Y, Leo E, Zhang H, Marchand C: DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010, 17 (5): 421-433. 10.1016/j.chembiol.2010.04.012.PubMedView ArticleGoogle Scholar
- Tse-Dinh YC: Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases. Infect Disord Drug Targets. 2007, 7 (1): 3-9.PubMedView ArticleGoogle Scholar
- Nollmann M, Crisona NJ, Arimondo PB: Thirty years of Escherichia coli DNA gyrase: from in vivo function to single-molecule mechanism. Biochimie. 2007, 89 (4): 490-499. 10.1016/j.biochi.2007.02.012.PubMedView ArticleGoogle Scholar
- Young D, Stark J, Kirschner D: Systems biology of persistent infection: tuberculosis as a case study. Nat Rev Microbiol. 2008, 6 (7): 520-528. 10.1038/nrmicro1919.PubMedView ArticleGoogle Scholar
- Takiff H, Guerrero E: Current prospects for the fluoroquinolones as first-line tuberculosis therapy. Antimicrob Agents Chemother. 2011, 55 (12): 5421-5429. 10.1128/AAC.00695-11.PubMedPubMed CentralView ArticleGoogle Scholar
- Aubry A, Fisher LM, Jarlier V, Cambau E: First functional characterization of a singly expressed bacterial type II topoisomerase: the enzyme from Mycobacterium tuberculosis. Biochem Biophys Res Commun. 2006, 348 (1): 158-165. 10.1016/j.bbrc.2006.07.017.PubMedView ArticleGoogle Scholar
- Unniraman S, Chatterji M, Nagaraja V: DNA gyrase genes in Mycobacterium tuberculosis: a single operon driven by multiple promoters. J Bacteriol. 2002, 184 (19): 5449-5456. 10.1128/JB.184.19.5449-5456.2002.PubMedPubMed CentralView ArticleGoogle Scholar
- Camus JC, Pryor MJ, Medigue C, Cole ST: Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv. Microbiology. 2002, 148 (Pt 10): 2967-2973.PubMedView ArticleGoogle Scholar
- Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C, Cambau E, Aubry A: A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother. 2012, 67 (4): 819-831. 10.1093/jac/dkr566.PubMedPubMed CentralView ArticleGoogle Scholar
- Karkare S, Yousafzai F, Mitchenall LA, Maxwell A: The role of Ca2+ in the activity of Mycobacterium tuberculosis DNA gyrase. Nucleic Acids Res. 2012, 40 (19): 9774-9787. 10.1093/nar/gks704.PubMedPubMed CentralView ArticleGoogle Scholar
- Rustad TR, Harrell MI, Liao R, Sherman DR: The enduring hypoxic response of Mycobacterium tuberculosis. PLoS One. 2008, 3 (1): e1502-10.1371/journal.pone.0001502.PubMedPubMed CentralView ArticleGoogle Scholar
- Brown AC, Eberl M, Crick DC, Jomaa H, Parish T: The nonmevalonate pathway of isoprenoid biosynthesis in Mycobacterium tuberculosis is essential and transcriptionally regulated by Dxs. J Bacteriol. 2010, 192 (9): 2424-2433. 10.1128/JB.01402-09.PubMedPubMed CentralView ArticleGoogle Scholar
- Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE, et al: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998, 393 (6685): 537-544. 10.1038/31159.PubMedView ArticleGoogle Scholar
- Dussurget O, Timm J, Gomez M, Gold B, Yu S, Sabol SZ, Holmes RK, Jacobs WR, Smith I: Transcriptional control of the iron-responsivefxbA gene by the mycobacterial regulator IdeR. J Bacteriol. 1999, 181 (11): 3402-3408.PubMedPubMed CentralGoogle Scholar
- Carroll P, James J: Assaying promoter activity using LacZ and GFP as reporters. Methods Mol Biol. 2009, 465: 265-277. 10.1007/978-1-59745-207-6_18.PubMedView ArticleGoogle Scholar
- Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, et al: Clustal W and Clustal X version 2.0. Bioinformatics. 2007, 23 (21): 2947-2948. 10.1093/bioinformatics/btm404.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.